Memorial Sloan-Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.

Results of an international study indicate that the investigational drug tivozanib is more effective and better tolerated than a currently approved therapy in delaying cancer growth.

Memorial Sloan-Kettering is the first and only hospital in New York, New Jersey, and Connecticut to offer a new, more patient-friendly approach for doctors to precisely pinpoint and remove small breast cancers.